Geneva-based PregLem ginned €22.5 million in its second venture round. San Francisco-based Sofinnova Partners led the round, with MVM Life Science Partners and NeoMed Management joining in. PregLem is developing a molecule that it in-licensed from France's HRA Pharma to treat pre-operative treatment of uterine myoma.
"In less than one year, PregLem has demonstrated its ability to in-license a portfolio of promising compounds to improve the treatment of a number of benign female reproductive health disorders," stated James Healy MD, PhD, General Partner at Sofinnova Ventures.
- check out the release for more info
- and here's the release on the most recent licensing deal